Middle Peak Medical has announced that it has raised US$8.5M in a Series A financing. The proceeds will provide capital for further development of Middle Peak’s technology for treating mitral valve disease.
According to a company press release, following the financing, Middle Peak will establish some of its clinical and regulatory operations in Europe. The company’s research and development centre will remain in Palo Alto.
Michael Lesh, chief executive officer and co-founder of the company, commented: “We are delighted to partner with Wellington, Seventure, and HTGF. They bring tremendous value to our operations. Our internal financing allowed us to show strong proof-of-concept of the Middle Peak mitral implant. We now have the resources to accelerate pre-clinical and clinical development. Middle Peak intends to bring significant benefit to patients with mitral regurgitation, the most common valvular heart disease.”